



Zevaskyn™ Gene Therapy Treatment Centers ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are manufacturer-approved treatment centers for which ETS has contracted rates in place or has access to rates through single case agreements for **Zevaskyn** (prademagene zamikeracel, pz-cel) which is approved to treat **recessive dystrophic epidermolysis bullosa (RDEB)**.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at clientservices@emergingtherapies.com.

▼ Denotes facilities at which ETS has gene therapy rates in place.

State	City	Program Listing
California	Palo Alto	Lucile Packard Children's Hospital
Colorado	Denver	Children's Hospital Colorado
Illinois	Chicago	Ann & Robert H. Lurie Children's Hospital of Chicago
Ohio	Cincinnati	Cincinnati Children's Hospital Medical Center ▼
Pennsylvania	Philadelphia	Children's Hospital of Philadelphia ▼